SCHEMBL22100721

SCHEMBL22100721

CC(=O)OCc1ccc(NC(=O)C(C)NC(=O)CNC(=O)CCCCCN2C(=O)C=CC2=O)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.40
▸ MEN1 O00255 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ HDAC2 Q92769 3/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ PTGS1 P23219 4/20 0.35
▸ PTGS2 P35354 4/20 0.35
▸ ALDH1A1 P00352 3/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ HPGD P15428 2/20 0.34
▸ MAPT P10636 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ OPRM1 P35372 1/20 0.34
▸ OPRD1 P41143 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20198075 0.92 SMN1; SMN2 (0.39) KMT2AMEN1LMNAHDAC2SMN1; SMN2
SCHEMBL19703232 0.88 KMT2A (0.39) KMT2AMEN1LMNAHDAC2SMN1; SMN2
SCHEMBL22147094 0.88 KMT2A (0.41) KMT2ALMNASMN1; SMN2RAB9APTGS1
SCHEMBL23867925 0.88 FOLH1 (0.37) KMT2AMEN1LMNASMN1; SMN2NPC1
SCHEMBL25681114 0.87 KMT2A (0.40) KMT2ASMN1; SMN2PTGS1PTGS2ALDH1A1
SCHEMBL19704786 0.87 KMT2A (0.37) KMT2AMEN1LMNAHDAC2SMN1; SMN2
SCHEMBL17722930 0.87 KMT2A (0.37) KMT2AMEN1LMNAHDAC2SMN1; SMN2
SCHEMBL17722936 0.87 KMT2A (0.37) KMT2AMEN1LMNAHDAC2SMN1; SMN2
SCHEMBL18264893 0.85 OPRK1 (0.35) KMT2AMEN1LMNASMN1; SMN2NPC1
SCHEMBL21516962 0.84 KMT2A (0.39) KMT2AMEN1LMNAHDAC2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3383909-B1 ANTI-HUMAN LRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE ABBVIE INC (US) 2020-06-17 — — EP disclosed
Send feedback